Allergan fails to demonstrate to FC that Apotex’s allegations of invalidity are not justified
2016 FC 344 - Apotex alleged in its Notice of Allegation and submissions that the ‘632 Patent was invalid because it was obvious and lacked utility. The FC found that the allegation was justified.
